Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

NeuroMetrix announces issuance of patent for DPNCheck core technology in China

NeuroMetrix announced that the State Intellectual Property Office of the People’s Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the company’s DPNCheck device.

DPNCheck device is a point-of-care test for peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

The patent claims cover the novel integrated design of the device that enables accurate and rapid measurement of sural nerve conduction, which is a standard neuropathy biomarker. Additional claims cover the automation algorithms and consumable biosensors.

China is dealing with an epidemic of diabetes. According to a recently published study in the Journal of the American Medical Association (JAMA), the prevalence of diabetes in the Chinese population has risen dramatically over the past decades to nearly 12% today.

The International Diabetes Federation (IDF) estimated in 2014 that over 96 million people in China had diabetes. This represents nearly 25% of the IDF estimated worldwide population of 387 million people with diabetes.

The Company is partnering with Omron Corporation to introduce DPNCheck to the China healthcare market.

DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy at an early stage allowing physicians to select appropriate treatment.

DPN is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.

DPNCheck is marketed in the U.S. to Medicare Advantage providers for profiling their patient population as well as guiding treatment. It is marketed in Japan by Omron Healthcare and in Mexico by Scienta Pharma.